TEMPO.CO, Jakarta - The Food and Drug Monitoring Agency (BPOM) on November 13, announced that it has revoked the emergency use authorization of COVID-19 medicines that contain Chloroquine Phosphate and Hydroxychloroquine Sulfate.

BPOM acting-head of food and drugs supervision, Togi Junice Hutadjulu, said that the revocation was based on recent global clinical studies and BPOM monitoring on the safety aspects of Chloroquine Phosphate and Hydroxychloroquine Sulfate.

The following are the name of the medicines and the pharmaceutical firms that held the emergency use authorization:

Medicines containing Hydroxychloroquine Sulfate:

1. Hydroxin, PT Dexa Medica
2. Hydroxychloroquine Sulfate, PT Dexa Medica
3. Hydroxychloroquine Sulfate, PT Imedco Jaya
4. Hyloquin, PT Imedco Jaya
5. Esele, PT Immortal Pharmaceutical Lab.
6. Hydroxychloroquine Sulfate, PT Kimia Farma
7. Hydroxychloroquine Sulfate, PT Pratapa Nirmala
8. Farneltik, PT Pratama Nirmala
9. Sanloquin, PT Sanbe Farma
10. Hydroxychloroquine Sulfate, PT Tempo Scan Pacific, Tbk
11. Hydroxychloroquine Sulfate, PT Tempo Scan Pacific

Medicines containing Chloroquine Phosphate:

1. Riboquin, PT Dexa Medica,
2. Riboquin, PT Dexa Medica,
3. Erlaquin, PT Erlangga Edi Laboratories (Erela)
4. Chloroquine Phosphate, PT Indofarma
5. Chloroquine Phosphate, PT Kimia Farma
6. Chloroquine Phosphate, PT Mersifarma Tirmaku Mercusuna,
7. Merquin 250, PT Mersifarma Tirmaku Mercusuna,
8. Chloroquine Phosphate, PT Mersifarma Tirmaku Mercusuna,
9. Merquin 250, PT Mersifarma Tirmaku Mercusuna,
10. Chloroquine Phosphate, PT Novapharin,
11. Chloroquine Phosphate, PT Novapharin,
12. Chloroquine Phosphate, PT Rama Emerald Multi Sukses

TEMPO.CO | RINI KUSTIANI